Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Naptumomab

Catalog No. T81704 Copy Product Info
🥰Excellent
Naptumomab (ABR-217620) is a tumor-targeted superantigen (TTS) fusion protein consisting of a Fab fragment targeting the 5T4 oncofetal antigen and a modified staphylococcal enterotoxin A (SEA/E-120). This product specifically recognizes 5T4 protein expressed on various solid tumors via the Fab fragment and potently activates T cells (primarily by binding to the TCR Vβ chain) through the superantigen component, inducing T cell-mediated cytotoxicity against tumor cells. It bypasses major histocompatibility complex (MHC) restriction to directly recruit and activate a large number of effector T cells into the tumor microenvironment.

Naptumomab

Copy Product Info
🥰Excellent
Catalog No. T81704

Naptumomab (ABR-217620) is a tumor-targeted superantigen (TTS) fusion protein consisting of a Fab fragment targeting the 5T4 oncofetal antigen and a modified staphylococcal enterotoxin A (SEA/E-120). This product specifically recognizes 5T4 protein expressed on various solid tumors via the Fab fragment and potently activates T cells (primarily by binding to the TCR Vβ chain) through the superantigen component, inducing T cell-mediated cytotoxicity against tumor cells. It bypasses major histocompatibility complex (MHC) restriction to directly recruit and activate a large number of effector T cells into the tumor microenvironment.

Naptumomab
Cas No. 1412892-09-1
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$2472-4 weeks2-4 weeks
5 mg$6222-4 weeks2-4 weeks
10 mg$9962-4 weeks2-4 weeks
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Naptumomab (ABR-217620) is a tumor-targeted superantigen (TTS) fusion protein consisting of a Fab fragment targeting the 5T4 oncofetal antigen and a modified staphylococcal enterotoxin A (SEA/E-120). This product specifically recognizes 5T4 protein expressed on various solid tumors via the Fab fragment and potently activates T cells (primarily by binding to the TCR Vβ chain) through the superantigen component, inducing T cell-mediated cytotoxicity against tumor cells. It bypasses major histocompatibility complex (MHC) restriction to directly recruit and activate a large number of effector T cells into the tumor microenvironment.
In vitro
In biochemical assays, Naptumomab binds with high affinity to 5T4-expressing tumor cells and simultaneously cross-links the T-cell receptor (TCR), leading to robust T-cell activation and proliferation; in cytotoxicity assays, the compound triggers the release of pro-inflammatory cytokines (such as IFN-γ and TNF-α) and mediates the efficient lysis of 5T4-positive renal cell carcinoma and lung cancer cell lines [1][2].
In vivo
In pharmacological studies using human tumor xenograft mouse models, systemic administration of Naptumomab results in a significant infiltration of activated T cells into the tumor mass and dose-dependent inhibition of tumor growth; the treatment enhances the recruitment of effector T cells and promotes localized anti-tumor immune responses [1][2].
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetTTS
Chemical Properties
Cas No.1412892-09-1
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Naptumomab | purchase Naptumomab | Naptumomab cost | order Naptumomab | Naptumomab in vivo | Naptumomab in vitro